Biowatch -- so do you think that the diagnostics will develop with the drug? Will companies screen the candidates for clinical trials using the same test that will eventually be used to screen for treatment; or will the testing be a later development? Right now, it would seem wise for a company to better characterize their target population and use that for trial testing. I suspect that even though that will narrow the eventual patient population, it may very well decrease development costs by reducing the size of the clinical trials.
Market Data 
Markets 
AI
